Advisory Committee

Pacsun Announces Leadership Transition

Retrieved on: 
Thursday, January 26, 2023
Storm, Metropolitan Museum of Art, Golden Gate Capital, Advisory Committee, Harvard Business School, Virtual influencer, Culture, Partnership, Ad Age, Kid, Woman, Generation Z, Fear, AI, Rest, Sport, Gen, Roblox, Advanced Management Program, Merchandising, LOS, Music, Senior, Management, Toy, God, Brie, Art, PacSun, Gloss (optics)

LOS ANGELES, Jan. 26, 2023 /PRNewswire/ -- Pacsun today announced a leadership transition in which Brie Olson, Pacsun President and Board member, will be appointed Co-Chief Executive Officer alongside Co-CEO Mike Relich, effective March 9, 2023. Alfred Chang will step down after 17 years with the company to join Fear of God, a key Pacsun brand partner, as its Chief Executive Officer. Mr. Chang will stay on as Pacsun's Co-CEO until March 8, 2023 to facilitate the transition and will remain a member of the Pacsun Board of Directors after joining Fear of God.

Key Points: 
  • Brie Olson Appointed Co-CEO Alongside Mike Relich, Effective March 9, 2023
    Alfred Chang to Become CEO of Fear of God; Will Remain on Pacsun Board of Directors
    LOS ANGELES, Jan. 26, 2023 /PRNewswire/ -- Pacsun today announced a leadership transition in which Brie Olson, Pacsun President and Board member, will be appointed Co-Chief Executive Officer alongside Co-CEO Mike Relich, effective March 9, 2023.
  • Mr. Chang will stay on as Pacsun's Co-CEO until March 8, 2023 to facilitate the transition and will remain a member of the Pacsun Board of Directors after joining Fear of God.
  • Ms. Olson has over two decades of experience in the retail industry, including 17 years at Pacsun, and has served as President and as a member of the Pacsun Board of Directors since May 2021.
  • Ms. Olson stated, "Pacsun aims to position our brand right alongside our customers – the cultural pioneers of the future.

HLTH Foundation Launches 'Techquity for Health' Coalition to Help Integrate Health Equity Standards into Healthcare Technology & Data Practices

Retrieved on: 
Thursday, January 26, 2023
Amazon Web Services, MPH, Advisory Committee, Health, BCPA, MBA, NTT DATA, Coalition, MSW, MPP, American Medical Association, Gundersen Health System, Stanford University School of Medicine, Bellin Health, Research, ResMed, Health equity, ViVe, Advisory, DO, Thought, Digital health, MS, Doctor of Philosophy, NTT, Management, Nursing, MD, CHIME

NEW YORK, Jan. 23, 2023 /PRNewswire/ -- HLTH Foundation, a 501(c)3 non-profit of HLTH, Inc., today announced the formation of the Techquity for Health Coalition, with a mission to assimilate health equity considerations into healthcare technology innovation and data practices across the industry. Additionally, the Coalition simultaneously launched a broad national survey of techquity in healthcare, available here, with a call for healthcare leaders to participate as respondents in this important and unique industry benchmark.

Key Points: 
  • NEW YORK, Jan. 23, 2023 /PRNewswire/ -- HLTH Foundation, a 501(c)3 non-profit of HLTH, Inc., today announced the formation of the Techquity for Health Coalition, with a mission to assimilate health equity considerations into healthcare technology innovation and data practices across the industry.
  • The Coalition defines techquity as the strategic design, development, and deployment of technology to advance health equity, and encompasses the notion that technology can inhibit advancements in health equity if not implemented intentionally and inclusively.
  • "Technology and data analytics offer enormous promise to improve care access and quality, but also add new layers of consideration for health equity," said Janna Guinen, Executive Director of the HLTH Foundation, which established the Coalition with Ipsos Healthcare as a strategic research partner.
  • The Coalition intends to develop and gain consensus around metrics, best practices and standards to operationalize techquity in healthcare, as well as monitor industry progress.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)

Retrieved on: 
Friday, February 10, 2023
Food, CNS, Court, Advisory Committee, GPM, Suite, BLA, Patient, Defendant, Regulation of tobacco by the U.S. Food and Drug Administration, FDA, Investment, Neuroblastoma, Therapy, News, Pharmaceutical industry

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On October 26, 2022, the FDA released its briefing document in advance of its Advisory Committee meeting to discuss the omburtamab BLA.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

New Publication Helps Young Black Americans Explore Career Paths in the Forest and Conservation Sector

Retrieved on: 
Tuesday, February 7, 2023
DEI, Forest, Assistant, African Americans, Community forestry, Historically black colleges and universities, Air pollution, Advisory Committee, SFI, United States Forest Service, Black Faces, White Spaces, Climate change, Research, Health, Sustainable Forestry Initiative, Recreational therapy, GIS, Student, Diversity, Tree, Natural Resources, PLT, Organization, Cohesion (linguistics), Project Learning Tree, Community, Quality of life, University of Kentucky, Consultant, Partnership, White, Employment, Education, School, Government, Urban green space, Chairperson, The Great Outdoors, Forestry, African, Journey, International Association of Students in Agricultural and Related Sciences, Audit, Management, Black, Agriculture, University

Many Black young adults are unaware of job opportunities in the forest and conservation sector, and unfortunately this stems from many reasons.

Key Points: 
  • Many Black young adults are unaware of job opportunities in the forest and conservation sector, and unfortunately this stems from many reasons.
  • “With less than 3% Black American representation in forest and conservation careers, these Black hidden figures are iconic to empowering our next generation of forest and conservation professionals,” said Dr. Marcus Bernard, National President of MANRRS.
  • “When students see Black professionals in the forest and conservation sector, they see themselves!
  • On August 2, 2021, SFI entered into a formal partnership with MANRRS to ensure young Black Americans have greater opportunities for rewarding careers in the forest and conservation sector.

Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)

Retrieved on: 
Tuesday, February 7, 2023
Marketing, RTF, Food, Food and Drug Administration, CNS, The Legal 500, Advertising, Cancer, Bias, Court, Therapy, Survival, Advisory Committee, Labour government, Patient, FDA, District court, Investment, Aerospace, Letter, News, Medical device, Pharmaceutical industry, Security (finance)

NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the common stock of Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB) between October 6, 2020 and October 28, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Joseph R. Seidman, Jr. at (877) 779-1414 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.
  • Y-mAbs is a clinical-stage biopharmaceutical company focused on developing antibody therapeutics and medicines for the treatment of cancer patients of all ages.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)

Retrieved on: 
Monday, February 6, 2023
Food, CNS, Court, Advisory Committee, GPM, Suite, BLA, Patient, Defendant, Regulation of tobacco by the U.S. Food and Drug Administration, FDA, Investment, Neuroblastoma, Therapy, News, Pharmaceutical industry

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On October 26, 2022, the FDA released its briefing document in advance of its Advisory Committee meeting to discuss the omburtamab BLA.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Veru Inc. - VERU

Retrieved on: 
Saturday, February 4, 2023
Food, COVID-19, Acute respiratory distress syndrome, Advisory Committee, Patient, Defense Department Advisory Committee on Women in the Services, News, Pharmaceutical industry

NEW YORK, Feb. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. (“Veru” or the “Company”) (NASDAQ: VERU).

Key Points: 
  • NEW YORK, Feb. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. (“Veru” or the “Company”) (NASDAQ: VERU).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Veru and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.

Amarin Mails Letter to Shareholders Highlighting New Board and Superior Leadership

Retrieved on: 
Thursday, February 2, 2023
Slate, Telephone, Our Boarding House, Scan, MD, Mass meeting, Interview, New Board, Novo Holdings A/S, Chairperson, ADS, Sarissa, Advisory Committee, Cardiology, Professional corporation, Bring Your Board!!, Internet, FDC, Merck, Letter, Management, Security (finance), Internet service provider, Renewable energy, Pharmaceutical industry, Amarin Corporation

DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) (“Amarin” or the “Company”) today announced that it has mailed a letter to shareholders in connection with the General Meeting of Shareholders urging shareholders to vote “AGAINST” all proposals on the WHITE proxy card. The General Meeting of Shareholders is scheduled to be held on February 28, 2023, and shareholders of record as of January 23, 2023, will be entitled to vote at the meeting.

Key Points: 
  • Your Board and management team are actively executing a thoughtful and practical strategic plan designed to create value now.
  • This is a NEW Amarin with a NEW Board, a NEW leadership team and a NEW strategy.
  • The Amarin Board now consists of nine directors – six of whom were appointed in the last year.
  • This is why we recommend that Amarin shareholders vote against adding Sarissa’s slate to the Board.

Y-MABS THERAPEUTICS, INC. (NASDAQ: YMAB) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB)

Retrieved on: 
Tuesday, January 31, 2023
Marketing, RTF, Food, Food and Drug Administration, CNS, The Legal 500, Advertising, Cancer, Bias, Court, Therapy, Survival, Advisory Committee, Labour government, Patient, FDA, District court, Investment, Aerospace, Letter, News, Tobacco, Pharmaceutical industry, Security (finance)

NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the common stock of Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”) (NASDAQ: YMAB) between October 6, 2020 and October 28, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • The lawsuit was filed in the United States District Court for the Southern District of New York and alleges violations of the Securities Exchange Act of 1934.
  • Y-mAbs is a clinical-stage biopharmaceutical company focused on developing antibody therapeutics and medicines for the treatment of cancer patients of all ages.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Veru Inc. - VERU

Retrieved on: 
Sunday, January 29, 2023
Food, COVID-19, Acute respiratory distress syndrome, Advisory Committee, Patient, Defense Department Advisory Committee on Women in the Services, News, Pharmaceutical industry

NEW YORK, Jan. 29, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. (“Veru” or the “Company”) (NASDAQ: VERU).

Key Points: 
  • NEW YORK, Jan. 29, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. (“Veru” or the “Company”) (NASDAQ: VERU).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Veru and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.